First-in-Human, Proof-of-Mechanism Phase 1 Study of the Oral MRGPRX2 Antagonist SEP-631 Utilizing Short-Wave Infrared Imaging to Assess Response to an Icatibant Skin Challenge

by Meaghan Kniffen-Wingo | Mar 1, 2026 | Uncategorized

SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria and Other Mast Cell-Mediated Diseases

by Oliver | Jun 14, 2025 | Uncategorized

Characterization of a Novel Oral Small Molecule PTH1R Agonist: Sustained Control of Serum Calcium and Modulation of Bone Biomarkers in TPTx Rats

by Septerna | Sep 30, 2024 | Uncategorized

Characterization of a Novel Oral Small Molecule PTH1R Agonist: Proof of Concept for an Alternative to Injectable Peptide-based Therapy for Hypoparathyroidism

by Septerna | Jun 3, 2024 | Uncategorized

A Novel Oral Small Molecule Antagonist Targeting TSHR Improves Hyperthyroidism in an in vivo Model of Graves’ Disease

by Septerna | Jun 3, 2024 | Uncategorized